AMICUS THERAPEUTICS, INC.
Key Highlights
- Amicus Therapeutics acquired by BioMarin Pharmaceutical Inc.
- Company transitioned from independent entity to wholly owned subsidiary.
- Strategic expansion of BioMarin's rare disease research pipeline.
- Integration of specialized drug portfolio into BioMarin operations.
Event Analysis
AMICUS THERAPEUTICS, INC. Material Event - The Company Has Been Acquired
If you have been following Amicus Therapeutics, there is major news. The company has been acquired and is no longer an independent, publicly traded business. Here is a breakdown of what happened and what it means for your investment.
1. What happened?
Amicus Therapeutics completed its merger with BioMarin Pharmaceutical Inc. As of April 27, 2026, Amicus is no longer an independent company. It now operates as a wholly owned subsidiary of BioMarin.
2. Why did it happen?
This acquisition follows the merger agreement announced in December 2025. By buying Amicus, BioMarin is expanding its reach and research pipeline in the rare disease market. BioMarin now controls Amicus’s specialized drug portfolio and clinical projects, integrating them into their larger operations.
3. What does this mean for your stock?
If you owned Amicus shares (ticker: FOLD), your investment has been cashed out.
- The Payout: Every share of Amicus stock you owned was canceled. In exchange, you have the right to receive $14.50 in cash per share, minus any applicable taxes.
- Delisting: The stock stopped trading on the Nasdaq after the market closed on April 27, 2026. You do not need to sell your shares yourself; your brokerage firm and the paying agent will handle the conversion to cash automatically.
- No more voting: The former Amicus directors have resigned, and the company is now a private subsidiary of BioMarin.
4. Who is affected?
- Investors: You are no longer a shareholder. Your investment is now worth exactly $14.50 per share. Check your brokerage statements to confirm the cash deposit.
- Patients: BioMarin now manages Amicus’s rare disease treatments. BioMarin has indicated that they are responsible for the continued manufacturing and distribution of these drugs.
- Employees: BioMarin has replaced the Amicus leadership team and now controls all Amicus facilities and research programs. The company didn't provide much specific detail regarding internal staffing changes in their public filings.
5. What happens next?
For you, the only step left is to monitor your brokerage account for the cash payment. Because the merger is complete and the shares are canceled, there is no more trading or price movement to track. You do not need to make any further trading decisions regarding this position.
6. The Bottom Line
Amicus is no longer a standalone public company. It has been absorbed into BioMarin Pharmaceutical Inc. If you held the stock, your investment has been converted into $14.50 per share, marking the end of your position in the company.
Disclaimer: I am an AI, not a financial advisor. This summary is for information only and is not professional investment advice. Always check with your brokerage regarding your account status and the timing of your cash payout.
Key Takeaways
- Amicus Therapeutics is no longer a publicly traded company.
- Investors will automatically receive $14.50 per share via their brokerage.
- No further trading or action is required by former shareholders.
- BioMarin now holds full control over all Amicus assets and clinical projects.
Why This Matters
This event marks the definitive end of Amicus Therapeutics as an independent public entity, signaling a major consolidation in the rare disease pharmaceutical sector. For investors, it represents a total exit event that removes the company from the public markets entirely.
Stockadora highlights this event because it requires immediate attention for portfolio reconciliation. With the stock delisted and shares converted to cash, investors must confirm their brokerage accounts reflect the final $14.50 per share payout to ensure their capital is properly accounted for.
Financial Impact
All outstanding shares canceled in exchange for a cash payout of $14.50 per share.
Affected Stakeholders
Learn More
About This Analysis
AI-powered summary derived from the original SEC filing.
Document Information
AI-Generated Analysis
This analysis is AI-generated from SEC filings. This is educational content, not financial advice. Always consult a financial advisor before making investment decisions.